Information on the target
Amneal Pharmaceuticals, Inc. (“Amneal”) has successfully completed its acquisition of Kashiv BioSciences, LLC (“Kashiv”), establishing a fully integrated global leader in the biosimilars sector. This strategic move enhances Amneal's capabilities in research, development, manufacturing, and commercialization, positioning the company to launch multiple biosimilars annually and extend its growth trajectory into the 2030s. The acquisition is a significant step towards Amneal's ambition to become America’s foremost provider of affordable medicines.
The integration of Kashiv’s advanced biologics capabilities with Amneal’s commercial scale creates one of the few fully integrated biosimilars platforms in the industry. This combination not only strengthens Amneal's existing portfolio but also opens avenues for future growth, particularly in light of the anticipated wave of biologic loss of exclusivity over the next decade.
Industry overview in the target’s specific country
The biopharmaceuticals industry in the United States is a dynamic and rapidly evolving sector, characterized by significant investment in research and development. The U.S. is home to a robust ecosystem of biotechnology firms, research institutions, and regulatory bodies that foster innovation and facilitate the development of new therapies. With a market projected to exceed $300 billion in biologics loss of exclusivity over the next decade, the opportunity for biosimilars is substantial.
In recent years, the U.S. government has implemented various initiatives aimed at increasing patient access to affordable biologic medicines. This includes regulatory pathways that streamline the approval process for biosimilars, thereby encouraging competition and driving down costs. The growing prevalence of chronic diseases and an aging population further amplify the demand for effective and affordable treatment options, positioning the biopharmaceuticals industry for sustained growth.
Moreover, the U.S. biopharmaceutical sector benefits from a strong intellectual property framework that incentivizes innovation while ensuring that new therapies can be brought to market efficiently. As a result, companies like Amneal are well-positioned to capitalize on the impending loss of exclusivity for numerous biologics, thereby expanding their market share and enhancing patient access to essential medicines.
As the industry continues to evolve, the integration of advanced technologies, such as artificial intelligence and machine learning, is expected to further accelerate drug discovery and development process…